个人信息

姓名：黄运远

学历：理学博士

职称：特聘副研究员

E-mail: yunyuanhuang@ccnu.edu.cn

教育与研究经历

2014年9月至2019年12月：华中师范大学化学学院学习，获理学博士学位；

2017年9月至2018年6月：华中农业大学生命科学学院博士联培；

2020年6月至2022年6月：华东理工大学药学院，从事博士后研究工作；

2022年7月至今：华中师范大学生命科学学院特聘副研究员。

科研情况

瞄准国家重大需求，面向人民生命健康，聚焦衰老、恶性肿瘤、心脑血管疾病候选新药研发及其作用机制研究，在Nat Aging、Acta Pharm Sin B、J Med Chem、 Eur J Med Chem、J Chem Inf Model等国内外期刊上发表SCI论文18篇，其中以第一作者或通讯作者发表SCI论文14篇，申请国家发明专利9项，授权5项；主持国家自然科学基金医学部青年项目一项、华中师范大学科研启动经费等。

研究领域：

1. 药物化学生物学：利用结构生物学方法开展基于靶标的药物发现

2.   药物设计：利用计算机辅助药物设计方法开展基于靶标结构的新型药物分子的合理设计

承担项目

1. 国家自然科学基金青年项目，主持，在研

2. 华中师范大学引进人才科研启动专项，主持，在研

代表性成果

1. Yixiang Xu^#, Chao Zhang^#, Kai Jiang^#, Xinchun Yang, Feng Chen, Zhiyang Cheng, Jinlong Zhao, Jiaxing Cheng, Xiaokang Li, Xin Chen, Luoyifan Zhou, Hao Duan, Yunyuan Huang*, Yaozu Xiang*, Jian Li*. Structural repurposing of SGLT2 inhibitor empagliflozin for strengthening anti-heart failure activity with lower glycosuria. Acta Pharm. Sin. B 2023, 13, 1671-1685

2. Donglei Shi^#, Wenwen Liu^#, Ying Gao#, Xinming Li, Yunyuan Huang, Xiaokang Li, Tony D. James, Yuan Guo*, Jian Li*. Photoactivatable senolysis with single-cell resolution delays aging. Nat. Aging 2023, 3, 297-312.

3. Wuqiang Wen^#, Hongxuan Cao^#, Yixiang Xu^#, Yanliang Ren*, Li Rao, Xubo Shao, Han Chen, Lixia Wu, Jiaqi Liu, Chen Su, Chao Peng, Yunyuan Huang*, Jian Wan*. N‑Acylamino saccharin as an emerging cysteine-directed covalent warhead and its application in the identification of novel FBPase inhibitors toward glucose reduction. J. Med. Chem. 2022, 65, 9126.

4. Xiaokang Li^#, Jinwen Li^#, Yunyuan Huang^#, Qi gang, Yan Fu, Yixiang Xu, Junyang Huang, Haolan You, Fei Mao, Jin Zhu, Huan Wang*, Haiyan Zhang*, Jian Li*. The Novel Therapeutic Strategy of Vilazodone-Donepezil Chimeras as Potent Triple Target Ligands for the Potential Treatment of Alzheimer’s Disease with Comorbid Depression. Eur. J. Med. Chem. 2022, 229, 114045.

5. Yunyuan Huang^#, Haiyan Xu^#, Pei Wang, Rurong Gu, Xiaokang Li, Yixiang Xu, Jiqun Wang, Sicong Qiao, Donglei Shi, Zhaobing Gao*, Jian Li*. Identification of guaifenesin−andrographolide as a novel combinatorial drug therapy for epilepsy using network virtual screening and experimental validation. ACS Chem. Neurosci. 2022, 13, 978-986.

6. Yunyuan Huang^#, Jiqun Wang^#, Donglei Shi, Manjiong Wang, Taotao Lu, Bei Jiang, Conglong Xia, Houwen Lin, Yixiang Xu*, Jian Li*. Rapid repurposing of novel combination drugs for the treatment of heart failure via a computationally guided network screening approach. J. Chem. Inf. Model. 2022, 62, 5223-5232.

7. Wuqiang Wen^#, Hongxuan Cao^#, Yunyuan Huang^#, Jie Tu^#, Chen Wan, Jian Wan*, Xingya Han, Han Chen, Jiaqi Liu, Li Rao, Chen Su, Chao Peng, Chunquan Sheng*, Yanliang Ren *. Structure-guided discovery of the novel covalent allosteric site and covalent inhibitors of fructose-1, 6-bisphosphate aldolase to overcome the azole-resistance of candidiasis. J. Med. Chem. 2022, 65, 2656.

8. Jiqun Wang^#, Yunyuan Huang^#, Kaixuan Shi ^#, Lingyuan Bao, Chaojiang Xiao, Tianyue Sun, Zhifan Mao, Jiali Feng, Zelan Hu, Zhenghan Guo, Jing Li, Bei Jiang, Wenwen Liu*, Jian Li*. Nicandra physalodes extract exerts antiaging effects in multiple models and extends the lifespan of caenorhabditis elegans via DAF-16 and HSF-1. Oxid. Med. Cell Longev. 2022, 2022, 3151071.

9. Yunyuan Huang^#, Yixiang Xu^#, Rongrong Song^#, Shuaishuai Ni^#, Jiaqi Liu, Yanhong Xu, Yanliang Ren*, Li Rao, Lingling Feng, Chen Su, Chao Peng, Jian Li*, Jian Wan*. Identification of the covalent allosteric C128-site of FBPase with disulfiram derivatives toward glucose reduction. J. Med. Chem. 2020, 63,6238.

10. Yixiang Xu^#, Yunyuan Huang^#, Rongrong Song^#, Yanliang Ren, Xin Chen, Chao Zhang, Fei Mao, Xikang Li, Jin Zhu, Shuaishuai Ni*, Jian Wan*，Jian Li*. Development of disulfide-derived fructose-1,6-bisphosphatase (FBPase) covalent inhibitors for the treatment of type 2 diabetes. Eur. J. Med. Chem. 2020, 203, 112500.

11. Lin Wei^#, Wuqiang Wen^#, Li Rao^#, Yunyuan Huang^#, Mengting Lei, Kai Liu, Saiya Hu, Rongrong Song, Yanliang Ren*, Jian Wan*. Cov_FB3D: A de novo covalent drug design protocol integrating the BA-SAMP strategy and machine-learning-based synthetic tractability evaluation. J. Chem. Inf. Model. 2020, 60, 4388.

12. Xinya Han^#, Yunyuan Huang^#, Lin Wei^#, Haifeng Chen, Yanrong Guo, Zilong Tang, Wei Hu, Qinfei Xia, Qi Wang, Jufeng Yan*, Yanliang Ren*. Biological evaluation and SAR analysis of novel covalent inhibitors against fructose-1,6-bisphosphatase. Bioorg. Med. Chem. 2020, 28, 115624.

13. Yunyuan Huang^#, Lin Wei^#, Xinya Han^#, Haifeng Chen^#, Yanliang Ren*, Yanhong Xu, Rongrong Song, Li Rao Chen Su, Chao Peng, Lingling Feng, Jian Wan*, Discovery of novel allosteric site and covalent inhibitors of FBPase with potent hypoglycemic effects. Eur. J. Med. Chem. 2019, 184, 111749.

14. Yunyuan Huang^#, Bo Chi^#, Yanhong Xu^#, Rongrong Song, Lin Wei, Li Rao, Lingling Feng, Yanliang Ren*, Jian Wan*. In silico screening of a novel scaffold for fructose-1,6-bisphosatase (FBPase) inhibitors. J. Mol. Graph. Model. 2019, 86, 142-148.

15. Xinya Han^#, Yunyuan Huang^#, Rui Zhang^#, San Xiao, Shuaihua Zhu, Nian Qin, Zongqin Hong, LinWei, Jiangtao Feng, Yanliang Ren, Lingling Feng, Jian Wan*. New insight into the binding modes of TNP-AMP to human liver fructose-1,6-bisphosphatase. Spectrochim. Acta A Mol. Biomol. Spectrosc. 2016, 165, 155-160.